PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33389386-0	2021	Suppression of TLR4/MyD88/TAK1/NF-kappaB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.	Bexarotene	98-108	toll-like receptor 4	Mus musculus	15-19	
33389386-3	2021	To elucidate these mechanisms, we investigated whether the TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in the CNS mediates the effect of bexarotene to prevent hyperalgesia in the LPS-induced inflammatory pain mouse model.	Bexarotene	143-153	toll-like receptor 4	Mus musculus	59-63	
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	toll-like receptor 4	Mus musculus	115-119	
33389386-7	2021	Likely, decreased activity of TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in addition to increased pro-inflammatory cytokine formation in the CNS of mice participates in the protective effect of bexarotene against hyperalgesia induced by LPS.	Bexarotene	201-211	toll-like receptor 4	Mus musculus	30-34